DJ Drucker, MA Nauck - The Lancet, 2006 - Elsevier Glucagon-like peptide 1 (GLP-1) is a gut-derived incretin hormone that
stimulates insulin and suppresses glucagon secretion, inhibits gastric emptying,
and reduces appetite and food intake. Therapeutic approaches for enhancing ... Cited by 403 - Related articles - All 10 versions
- ►diabetesjournals.org CF Deacon - Diabetes, 2004 - Am Diabetes Assoc Glucagon-like peptide (GLP)-1 is an incretin hormone with potent
glucose-dependent insulinotropic and glucagonostatic actions, trophic effects on
the pancreatic β-cells, and inhibitory effects on gastrointestinal ... Cited by 154 - Related articles - BL Direct - All 5 versions
- ►endojournals.org F Fehse, M Trautmann, JJ Holst, AE Halseth … - Journal of Clinical Endocrinology & Metabolism, 2005 - Endocrine Soc Context: First-phase insulin secretion (within 10 min after a sudden rise in
plasma glucose) is reduced in type 2 diabetes mellitus (DM2). The incretin
mimetic exenatide has glucoregulatory activities in DM2, including glucose- ... Cited by 122 - Related articles - BL Direct - All 4 versions
T Vilsbøll, M Zdravkovic, T Le-Thi, T Krarup, … - Diabetes Care, 2007 - Am Diabetes Assoc Main inclusion criteria were patients aged ≥18 years with type 2 diabetes and
A1C ≥7.5 and ≤10.0% (diet) or ≥7.0 and ≤9.5% (mono–oral antidiabetes
drug); previous therapy was discontinued. Fasting plasma glucose (FPG) at ... Cited by 116 - Related articles - BL Direct - All 5 versions
MA Nauck, JJ Meier - Regulatory peptides, 2005 - Elsevier Glucagon-like peptide 1 (GLP-1) was discovered as an insulinotropic gut hormone,
suggesting a physiological role as an incretin hormone, ie, being responsible,
in part, for the higher insulin secretory response after oral as compared ... Cited by 107 - Related articles - All 6 versions
CF Deacon, B Ahrén, JJ Holst - eid, 2004 - informahealthcare.com Inhibitors of the enzyme dipeptidyl peptidase IV (DPP IV) are of increasing
interest to both diabetologists and the pharmaceutical industry alike, as they
may become established as the next member of the oral antidiabetic class of ... Cited by 102 - Related articles - All 7 versions
- Free from Publisher H Harder, L Nielsen, TDT Thi, A Astrup - Diabetes Care, 2004 - Am Diabetes Assoc RESULTS—After 8 weeks, liraglutide reduced fasting serum glucose (liraglutide,
−1.90 mmol/l, and placebo, 0.27 mmol/l; P = 0.002) and HbA 1c (liraglutide,
−0.33%, and placebo, 0.47%; P = 0.028) compared with placebo. No change ... Cited by 89 - Related articles - BL Direct - All 7 versions
- ►nih.gov DJ Drucker - Journal of Clinical Investigation, 2007 - Am Soc Clin Investig The gastrointestinal tract has a crucial role in the control of energy
homeostasis through its role in the digestion, absorption, and assimilation of
ingested nutrients. Furthermore, signals from the gastrointestinal tract ... Cited by 82 - Related articles - BL Direct - All 11 versions
- ►glucagon.com [PDF] - Free from Publisher MC Riddle, DJ Drucker - Diabetes Care, 2006 - Am Diabetes Assoc Current therapies for type 2 diabetes are frequently associated with inadequate
control of postprandial hyperglycemia, weight gain, and, in the case of oral
agents, loss of efficacy over time. A better understanding of physiological ... Cited by 71 - Related articles - BL Direct - All 10 versions
BE Dunning, JE Foley, B Ahren - Diabetologia, 2005 - Springer Abstract Although there is abundant evidence that hyper- glucagonaemia plays a
key role in the development of hy- perglycaemia in type 2 diabetes, efforts to
understand and correct this abnormality have been overshadowed by the ... Cited by 70 - Related articles - BL Direct - All 3 versions
